PDCD1 and neoplasm: The resistance mechanisms to anti-PD-1/PD-L1 immunotherapy in HNSCC were divided into four categories: tumor cell adaptation, T-cell function and proliferation, change in the tumor microenvironment, and use of alternative immune checkpoint [11].